Here I briefly discuss a challenging case of a patient who has an exon 20 mutation in the EGFR gene, which isn’t one of the mutation types associated with a high probability of responding well to an oral EGFR inhibitor. I cover the approach I favored and also some limited information that has just emerged to help clarify what we might expect for patients with an uncommon to rare variant of an EGFR mutation (~5% of mutations detected).
Here’s the second half of the presentation by Dr. Gerard Silvestri, expert pulmonologist and critical care specialist at the Medical University of South Carolina in Charleston, on pulmonary complications from lung cancer treatment. In this part, he briefly covers the side effects of some systemic targeted therapies used as a treatment for lung cancer, then covers the important topic of radiation pneumonitis in some detail.
Here is the podcast in video and audio versions, along with the transcript and figures.